Phathom Pharmaceuticals, Inc. — Director's Dealing 2023

Apr 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2023-04-06

Reporting Person: Curran Terrie (Director, President and Chief Executive)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-06	Common Stock	P	12919	$7.8199	Acquired	188290	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2235.9	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.79 to $7.85. The Reporting Person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.